- Home
- NRIX vs CET Comparison
NRIX vs CET Comparison
Compare NRIX & CET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- CET
- Stock Information
- Founded
- NRIX 2009
- CET 1929
- Country
- NRIX United States
- CET United States
- Employees
- NRIX N/A
- CET N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- CET Finance/Investors Services
- Sector
- NRIX Health Care
- CET Finance
- Exchange
- NRIX Nasdaq
- CET Nasdaq
- Market Cap
- NRIX 1.1B
- CET 1.2B
- IPO Year
- NRIX 2020
- CET N/A
- Fundamental
- Price
- NRIX $12.06
- CET $46.10
- Analyst Decision
- NRIX Strong Buy
- CET
- Analyst Count
- NRIX 17
- CET 0
- Target Price
- NRIX $30.71
- CET N/A
- AVG Volume (30 Days)
- NRIX 739.8K
- CET 22.7K
- Earning Date
- NRIX 07-10-2025
- CET 01-01-0001
- Dividend Yield
- NRIX N/A
- CET 4.84%
- EPS Growth
- NRIX N/A
- CET 26.33
- EPS
- NRIX N/A
- CET 9.95
- Revenue
- NRIX $56,417,000.00
- CET $23,698,535.00
- Revenue This Year
- NRIX $15.43
- CET N/A
- Revenue Next Year
- NRIX N/A
- CET N/A
- P/E Ratio
- NRIX N/A
- CET $4.67
- Revenue Growth
- NRIX N/A
- CET 11.75
- 52 Week Low
- NRIX $8.18
- CET $40.24
- 52 Week High
- NRIX $29.56
- CET $49.51
- Technical
- Relative Strength Index (RSI)
- NRIX 66.26
- CET 54.14
- Support Level
- NRIX $9.67
- CET $45.89
- Resistance Level
- NRIX $10.79
- CET $46.63
- Average True Range (ATR)
- NRIX 0.60
- CET 0.59
- MACD
- NRIX 0.27
- CET -0.10
- Stochastic Oscillator
- NRIX 84.13
- CET 16.76
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About CET Central Securities Corporation
Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital. The company invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.